Gem Wu
19 followers · 20 following · 858 views
on the atlas · 34
- BANKSY unifies cell typing and tissue domain segmentation for scalable spatial omics data analysis | Nature Genetics1 savers
- Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications: Cancer Cell1 savers
- How I treat diffuse large B-cell lymphoma - ESMO Open1 savers
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Blood | American Society of Hematology1 savers
- Genomic Classification and Prognosis in Acute Myeloid Leukemia | New England Journal of Medicine1 savers
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia | New England Journal of Medicine1 savers
- A novel RT‐qPCR assay for quantification of the MLL‐MLLT3 fusion transcript in acute myeloid leukaemia - Abildgaard - 2013 - European Journal of Haematology - Wiley Online Library1 savers
- Autoimmune hemolytic anemia | Hematology, ASH Education Program | American Society of Hematology1 savers
- The passion of the real - No Subject - Encyclopedia of Psychoanalysis - Encyclopedia of Lacanian Psychoanalysis1 savers
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Nature1 savers
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Nature1 savers
- Occupation, hobbies, and acute leukemia in adults - ScienceDirect1 savers
- The EBMT Handbook1 savers
- WHO or International Consensus Classification: Is the Difference Worth It? | Journal of Clinical Oncology1 savers
- 名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncology1 savers
- Clonal hematopoiesis in human aging and disease | Science1 savers
- 利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer Lab1 savers
- Guidance for Industry1 savers
- Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes | Blood | American Society of Hematology1 savers
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Journal of Clinical Oncology1 savers
- RAS靶向癌症治療的現況與未來趨勢|自然評論臨床腫瘤學 --- The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology1 savers
- Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel | Blood Cancer Journal1 savers
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Blood | American Society of Hematology1 savers
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements | Blood Cancer Journal1 savers
- Manuscript Preparation | Clinical Infectious Diseases | Oxford Academic1 savers
- 終結檳榔三不管！監察院糾正行政院怠忽管理，立委承諾推動「檳榔防制專法」 | 上下游1 savers
- RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia - PubMed1 savers
- 客观评价习近平（四万字，慎读） - 方舟與中國 (@arkincollapse)1 savers
- Academic clinician–scientists risk becoming an endangered species | Nature Medicine1 savers
- Savoir | 追悔於「能及」與「莫及」之間—台灣為何適合《葬送的芙莉蓮》？1 savers
- Trisomy 8 Remodels Chromatin and Activates Transcription of Runx1-Target Genes in Hematopoietic Stem Cell - ScienceDirect1 savers
- 用R畫存活曲線Survival curve // 有完沒完RRR1 savers
- How to Lose Time and Money6 savers
- Curius / Onboarding2704 savers
highlights · 323
We carry out a clinical examination before every treatment cycle to assess the clinical response and do a CT scan after three cycles and a PET scan after completion of treatment.
How I treat diffuse large B-cell lymphoma - ESMO OpenWe carry out a clinical examination before every treatment cycle to assess the clinical response and do a CT scan after three cycles and a PET scan after completion of treatment.
How I treat diffuse large B-cell lymphoma - ESMO OpenINFLUENCE OF CO-OCCURRING MUTATIONS ON CLINICAL OUTCOMES
Genomic Classification and Prognosis in Acute Myeloid Leukemia | New England Journal of MedicineUsing the HotNet algorithm,27 we identified six subnetworks of a genome-scale protein–protein interaction network that had significant mutations (P<0.001).
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia | New England Journal of MedicineUsing the HotNet algorithm,27 we identified six subnetworks of a genome-scale protein–protein interaction network that had significant mutations (P<0.001).
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia | New England Journal of MedicineA novel RT-qPCR assay
A novel RT‐qPCR assay for quantification of the MLL‐MLLT3 fusion transcript in acute myeloid leukaemia - Abildgaard - 2013 - European Journal of Haematology - Wiley Online LibraryInvestigations in patients presenting with AIHA
Autoimmune hemolytic anemia | Hematology, ASH Education Program | American Society of Hematologydisplacement of BRD3/4, PAFc and SEC components from chromatin
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | NatureBCL2, C-MYC and CDK6
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Natureefficacy of I-BET151 against human leukaemia stem cells
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Naturehuman and murine MLL-fusion leukaemic cell lines
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Naturepolymerase-associated factor complex (PAFc)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Natureglobal proteomic strategy
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Naturesuper elongation complex (SEC)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Naturesmall molecule inhibitor of the BET family, GSK1210151A (I-BET151)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Natureglobal proteomic strategy
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | NatureLong-term workers had an odds ratio of 8.5, although few of the study participants were employed in this industry and confidence intervals were wide. Ionizing radiation impairs hematopoiesis through a variety of mechanisms, including direct damage to hematopoietic stem cells [70] . Increased risk of leukemia incidence and mortality has been associated with radiation exposure in the nuclear industry in several previous investigations, including a study of nuclear industry workers in the United Kingdom [17] , [18] , a study of mortality among Russian nuclear workers [20] , and a study of nuclear…
Occupation, hobbies, and acute leukemia in adults - ScienceDirectlong-term employment in the nuclear power or auto manufacturing industry was associated with an increased risk of AML
Occupation, hobbies, and acute leukemia in adults - ScienceDirectthe nuclear power industry
Occupation, hobbies, and acute leukemia in adults - ScienceDirectBefore the introduction of antifungal prophy - laxis
The EBMT Handbookeflect areas of uncertainty where evidence is currently insufficient or arbitrary thresholds
WHO or International Consensus Classification: Is the Difference Worth It? | Journal of Clinical OncologyMy expectation is that at our institutions, we will step back in time 25+ years and provide two diagnoses according to the WHO 5th edition and the ICC classifications, both for completeness and to ensure that our reports are readily interpretable when patients are seen in consultation at other institutions.
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologynodular lymphocyte predominant B-cell lymphoma
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologynodular lymphocyte predominant Hodgkin lymphoma
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical OncologyB prolymphocytic leukemia and hairy cell leukemia variant are maintained as discrete entities in the ICC but are lumped together in the WHO 5th edition under a new morphologically defined entity, splenic B-cell lymphoma/leukemia with prominent nucleoli. The wisdom of this change seems questionable, both because most practicing hematopathologists have a sense that B prolymphocytic leukemia and hairy cell leukemia variant are distinct and recognizable and because new neoplastic entities defined mainly by morphologic features rarely stand up to closer molecular characterization.
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical OncologyThe rationale for these distinctions is unclear or seems to be simply a matter of opinion in many instances, creating diagnostic complexity that not even a hematopathologist could love, never mind our clinical colleagues and trainees who are new to the field.
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologymerely expected that blasts should be increased
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical OncologyICC, the diagnosis of AML with NPM1 mutation or rearrangements of multiple types (eg, PML::RARA, RUNX1::RUNX1T1, CBFB:MYH11, KMT2A, MECOM, NUP98, etc) requires > 10% blasts or blast equivalents
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical OncologyICC creates a new diagnostic category, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologymyeloid neoplasms show varying degrees of maturation abnormalities
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologymostly related to naming, subclassification, and diagnostic criteria of specific entities
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologynone of the editors or members of the clinical advisory committee who contributed to the most recent prior WHO classification (the revised 4th edition) were part of the group subsequently charged with producing the 5th WHO classification
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical Oncologysuffice it to say that the dispute largely centers on who gets to choose who participates in the process
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical OncologyI remember all too well a time when there was no consensus for the classification of hematologic malignancies. Pathologic diagnoses often included two or more names for the same entity or bore different names in parts of the world where one classification system was favored over others. Diagnostic criteria varied widely, and there was not even agreement as to whether some entities truly existed. Understandably, these uncertainties often lead to consternation and, not infrequently, confusion among physicians and patients.
名字裡有什麼？血液病理學分類分裂的後果臨床腫瘤學雜誌 --- What is in a Name? Consequences of the Classification Schism in Hematopathology | Journal of Clinical OncologyWe wanted to share our experience and solutions that worked for us so that not everybody has to reinvent the wheel.
利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer Labmappings can easily cause over- or under-representation of gene sets due to cross identification mismatches.
利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer Labgene identification mapping from one provider to another often becomes essential
利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer LabA practical solution that works nicely for us is to import such gene sets into Google Spreadsheets (for collaborative editing, taking care to ensure that gene names aren’t converted to dates) and then reduce them to GMT files to be used in the analysis.
利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer Labour database of gene sets should evolve with our knowledge, but in reality, it is far behind our current knowledge due to the slow nature of the literature-based curation process.
利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer LabGene sets often represent biologically meaningful groupings: for example, all genes that are active during controlled cell death. It is common to see these gene sets being referred as pathways and it is for this reason that GSEA is also known as pathway analysis. This name, unfortunately, leads to the following misconceptions regarding the whole approach: 1) Pathways are well-defined gene sets and they do not change; 2) There is no room for customization of the database of gene sets used in the enrichment analysis.
利用癌症免疫學收藏品擴展基因集富集分析 · Hammer Lab --- Extending Gene Set Enrichment Analysis with Cancer Immunology Collections · Hammer LabDeath from any cause.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes | Blood | American Society of HematologyDeath from any cause.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes | Blood | American Society of HematologyRFS is defined only for patients who achieve CR, and is measured from the date of attaining the leukemia-free state (as discussed previously) until the date of AML relapse or death from any cause, whichever occurs first.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Journal of Clinical OncologyInhibitors of the KRASG12C variant constitute a potential breakthrough in the treatment of many cancer types, particularly non-small-cell lung cancer
RAS靶向癌症治療的現況與未來趨勢|自然評論臨床腫瘤學 --- The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical OncologyKRASG12C-mutant cancers
RAS靶向癌症治療的現況與未來趨勢|自然評論臨床腫瘤學 --- The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncologypanel of 13 global experts, following a meeting in August 2022
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel | Blood Cancer Journalt(v;11q23.3); KMT2A rearranged
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Blood | American Society of Hematologyt(9;11)(p21.3;q23.3); MLLT3-KMT2A‡
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Blood | American Society of HematologyKMT2Ar are founding events in this leukemia and that relapse following current treatments is not driven by the acquisition of novel drivers in the absence of KMT2Ar
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements | Blood Cancer Journalreports on the prognostic impact of various translocations causing KMT2Ar are conflicting
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements | Blood Cancer Journal